Clinical research firm CenExel has announced that it will acquire Apex Innovative Sciences, which is the parent of Collaborative Neuroscience Research (CNS) and Hassman Research Institute (HRI).
The Salt Lake City–based company will rename the latter two organizations CenExel CNS and CenExel HRI, respectively.
CenExel CNS and CenExel HRI operate five clinical research sites based in California and New Jersey.
The leadership of the two organizations will remain unchanged, with Dr. David Walling continuing to guide the research at CenExel CNS and Dr. Howard Hassman doing so at CenExel HRI.
CenExel has been on a hiring spree this year. In January, the firm picked up the Rocky Mountain Movement Disorders Center, which specialized in researching movement disorders. In February, CenExel announced the acquisition of CTSdatabase, a developer of a clinical trial subject registry. In May, the company acquired iResearch, a multi-specialty research site business.
Following the most recent acquisition, CenExel CEO Tom Wardle boasted in a press release that the company now operates “the foremost therapeutically-focused clinical research site network in the neurosciences.”
In all, the company’s research units have more than 500 inpatient beds.
The company can support clinical research from Phases 1 through 4.
Filed Under: clinical trials, Drug Discovery